Cancer knows no borders
International Cancer Proteogenome Consortium (ICPC)
Learn more about the ICPC and discover how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.
The International Cancer Proteogenome Consortium (ICPC) is a voluntary scientific organization that provides a forum for collaboration among some of the world's leading cancer and proteogenomic research centers.
Launched in late 2016, the ICPC was catalyzed by the Cancer MoonshotSM (White House Fact Sheet - Australia; White House Fact Sheet - United Nations Good Summit) to encourage international cooperation and investment in cancer research and care, as well as new efforts in precision medicine.
The ICPC brings together more than a dozen countries to study the application of proteogenomic analysis in predicting cancer treatment success. Participants pledge to share data and results with researchers worldwide, hastening progress in patient care.
Current institutions include (alphabetical order)
Australia
Team: Macquarie University, Children’s Medical Research Institute, Garvan Institute of Medical Research, and Bioplatforms Australia Ltd.
Cancer focus: all cancer types, including sarcoma, colorectal cancer, melanoma, childhood cancers
Canada/Germany
Team: McGill University, University of Victoria, University of British Columbia, and Leibniz Institute for Analytical Sciences
Cancer focus: lung cancer, breast cancer, colorectal cancer, melanoma, cancers in adolescents and young adults
China
Team: Shanghai Institute of Materia Medica, Chinese Academy of Science, and Fudan University
Cancer focus: liver cancer and other frequent cancer types in Chinese population
India
Team: Indian Institute of Technology Bombay, and Tata Memorial Centre
Cancer focus: breast cancer, head & neck cancer, cervical cancer
Japan
Team: National Cancer Center Japan
Cancer focus: sarcoma
South Korea
Team: Korea Institute of Science and Technology
Cancer focus: lung cancer (adenocarcinoma)
Team: Korea University
Cancer focus: gastric cancer, pancreatic ductal adenocarcinoma
Team: National Cancer Center, Korea
Cancer focus: early onset breast cancer, cervical cancer, cholangiocarcinoma, gastric cancer
Team: Daegu Gyeongbuk Institute of Science and Technology, and Kyung Hee University
Cancer focus: breast cancer, brain cancer
Spain
Team: Josep Carreras Leukaemia Research Institute
Cancer focus: leukemia
Sweden
Team: Lund University
Cancer focus: melanoma
Switzerland
Team: ETH Zürich
Cancer focus: prostate cancer, melanoma
Taiwan
Team: Academia Sinica
Cancer focus: lung cancer, breast cancer
Team: Chang Gung University
Cancer focus: oral squamous cell carcinoma, colorectal cancer
The Netherlands
Team: Amsterdam UMC
Cancer focus: colon, pancreatic, breast cancer
United Kingdom
Team: University of Manchester and University of Dundee
Cancer focus: esophageal cancer, prostate cancer
United States
Team: NCI Clinical Proteomic Tumor Analysis Consortium
Cancer focus: (potentially) glioblastoma multiforme, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic ductal adenocarcinoma, clear cell kidney carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, sarcomas, uterine corpus endometrial carcinoma, acute myeloid leukemia
Learn More
Visit the ICPC Portal for completed projects, publications, news and media.